American health care needs to change to prevent price gouging

The Breeze:  War Room, October 11, 2015
by Kevan Hulligan

Sometimes the depth of human greed surprises even me.

Last month, Martin Shkreli, former hedge fund manager and CEO of Turing Pharmaceuticals, bought the rights to a drug called Daraprim. It’s a drug that’s been used to treat infections that are common in those suffering from cancer or HIV. Shkreli raised the price of this potentially life-saving drug from $18 a pill to $750. You can imagine the public outcry that occurred.

The backlash was enormous, especially when Shkreli did TV interviews that didn’t help change the image of him as a callous, greedy CEO out to make mounds of cash off the back of human misery. After all the rage and condemnation, he announced that he would change the price of the drug to a more affordable figure.

The only problem is that Shkreli hasn’t changed the price of the drug at all. When ABC checked pharmacies in Arizona, New York and Nevada, it found that the drug was being sold for somewhere between $888 and a ridiculous $906 after including pharmacy fees.

While this may be an example that got a lot of media and public attention, this is indicative of a much larger problem in the United States.